TUMOR ENZYME DETECTION

Abstract: A monospecific antibody prepared in response to cathepsin B proteinase by homogenizing purified cathepsin B proteinase upon dialyzing to remove ampholines, injecting a proteinase emulsion intramuscularly into an animal, reinjecting the animal with the proteinase emulsion, with drawing blood of the animal after sufficient time elapse for antibody production and isolating the monospecific antiserum from the blood.

Description: TUMOR ENZYME DETECTION Field of the Invention This invention relates to the production, purification and use of antibodies specific to enzymes which may be indicators of cancer involvement. In particular, the enzymes belong to the class called thiol proteinases. Background of The Invention The distinguishing features of malignant disease are the capacity of tumors for uncontrolled growth, local invasion of host tissue and dis¬ semination of tumor cells into the circulatory system. The action of proteo- lytic enzymes has been implicated in many of the events leading to the development of extensive malignant disease. Degradation of connective tissue and basement membrane components are instrumental in the local spread of tumor cells, as well as in their migration into and out of the circulatory system. • Lysosomal enzyme cathepsin B is a thiol proteinase present in most, if not all animal tissues. Thiol proteinase secretions have been seen in primary malignant breast tumors and metastases for patients with previous breast carcinomas. In order to follow-up this possible link between thiol proteinases and cancer activity, assays were developed for thiol proteinases. However, since more than one proteinase can degrade the same synthetic substrate, a less specific demonstration of a particular proteinase is achieved than by immunological methods. Antiserum to the thiol proteinase cathepsin B has been raised but no data was published regarding the specificity to the antiserum. See Barrett, A. J., "Cathepsin B and Other Thiol Proteinases," In Proteinases In Mammalian Cells and Tissues. (1977) In order to be useful as a diagnostic or locational tool, antiserum to cathepsin B must be completely specific as an absolute requirement. An article describing the preparation and characterization of a monospecific antiserum to human cathepsin B was published in 1981, by Poole, Mort and Decker in The Journal of Histochemistry Q--.ΪPI Y#IrO and .Cytochemistry, entitled "Immunofluoreseent Localization of Cathepsin B and D in Human Fibroblasts," Vol. 29, No. 5, pp. 649-657. Brief Summary of the Invention Monospecific antisera are provided to normal and tumor cathepsin B proteinases by injecting a purified proteinase into an animal. The animal's body then produces antiserum to the proteinase which is removed from the blood and highly purified. Once an antiserum is available that reacts with only one specific antigen, the proteinase first injected, the antiserum is used to determine the presence and amount of the proteinase in tissue samples or sera of a patient. One object of the present invention is to raise purified specific antisera to cathepsin B and cathepsin B-like proteinases. Another object is to provide an immunoassay for the determina¬ tion of proteinases in serum with greater specificity than activity assays. Still another object is to provide a process to raise monospecific antiserum to the tumor cathepsin B proteinase which may then be used to detect tumors in patients. Detailed Description of the Invention In order to prepare monospecific antiserum, the antigen, which is the enzyme, must be highly purified. Cathepsin B is a thiol proteinase found in most animal tissues, No. EC3.4.22.1 in the Enzyme Nomenclature List, (1972) with a molecular weight of about 28,000. It is purified from human liver following a modification of the method of Barrett, A. J. in "Cathepsin B and other Thiol Proteinases" in Proteinases in the Mammalian Cells and Tissues, pages 181-208, (1977). After the gel filtration step, the substantially pure enzyme was subjected to preparative isoeleetric focusing in a Sephadex G- 5 superfine flat bed using a 2 percent pH 5-7 ampholine (LKB) gradient. For anti¬ body preparation the main activity band was focused as above but in a pH 4-6 ampholine (BioRad) gradient. The cathepsin B, 0.5 mg in 3ml is dialyzed against 50 mM sodium acetate, 200mM NaCl and ImM Ethylenedϊamino tetraacetate, hereinafter EDTA at a pH of 5.5 to remove ampholines and then homogenized for 15 seconds with 5 ml Freund's complete adjuvant using a Tissuizer homogenizer. The emulsion is injected intramuscularly into a sheep at four sites. After two weeks, a further 0.25 mg of enzyme in 1.5 ml of buffer emulsified with 2.5 ml of Freund's complete adjuvant is injected as before. The animal is bled out by intracarotid catheterization after a further 11 days. Monospecific antiserum or antibody to cathepsin B may then be isolated from the animal's blood by any of a number of well known techniques. One technique of purifying the antibody is described by Poole et al, in Arthritis Rheum 19:1295, (1976). The specificity of the antiserum produced is demonstrated by the formation, on double immunodiffusion, of single precipitin lines with pure cathepsin B and crude human liver homogenate that show a reaction of the identity. That the antiserum gave no precipitin line at pH 6.5 against liver homogenate is also an indication of monospecificity. On crossed immuno- electrophoresis (migration in both dimensions taking place at pH 8.3) human liver homogenate gave a single rocket. This antiserum reacts only with denatured enzyme, thus, on double immonodiffusion a precipitin line will form only if cathepsin B is denatured. A related cathepsin B-like proteinase has been found in human malignant tumors with a molecular weight of about 36,000 and an alkaline pH stability unlike normal cathepsin B. Monospecific antiserum to this tumor thiol proteinase may be produced in the same method as described above. While sheep may be used as described to produce the antiserum to human cathepsin B, other animals may be used. Antiserum to human cathepsin B as raised in a rabbit, and antiserum to rabbit cathepsin B as raised in sheep have been prepared following the procedures in this disclosure. While the invention has been described with reference to various specific preferred embodiments thereof, it is to be appreciated that modifica¬ tions and variations can be made without departing from the scope of the invention which is limited only as defined in the appended claims. / -y λ;Lirr

Claims: WHAT IS CLAIMED: 1. A monospecific antibody prepared in response to cathepsin B proteinase. 2. A monospecific antiserum to cathepsin B proteinase of the type produced by the process, comprising essentially the steps of: (a) producing a proteinase emulsion by homogenizing purified cathepsin B proteinase after dialyzing to remove ampholines; (b) injecting the proteinase emulsion intramuscularly into an animal; (c) reinjeeting the animal with the proteinase emulsion; (d) withdrawing blood of the animal after sufficient time elapses for antibody production; (e) isolating the monospecific antiserum from the blood. 3. The process of producing a monospecific antiserum to cathepsin B proteinase comprising essentially the steps of: (a) producing a proteinase emulsion by homogenizing purified cathepsin B proteinase after dialyzing to remove ampholines; (b) injecting the proteinase emulsion intramuscularly into an animal; (e) reinjeeting the animal with the proteinase emulsion; (d) withdrawing blood of the animal after sufficient time elapses for antibody production; and (e) isolating the monospecific antiserum from the blood. 4. The process of Claim 3 wherein blood of the animal is withdrawn 11 days after the second injection of proteinase emulsion. 5. The process of Claim 3 wherein the enzyme is dialyzed against 50 mM sodium acetate, 200 mM NaCL and 1 raM EDTA at pH 5.5. 6. The process of Claim 3 wherein purified cathepsin B proteinase is further purified by isoelectric focusing in a Sephadex G-75 superfine flat bed with a 2 percent pH 4-6 ampholine (BioRad) gradient. 7. The process of Claim 3 wherein the animal is reinjected with proteinase emulsion after two weeks. 8. The process of Claim 3 wherein the proteinase is homogenized with an adjuvant. 9. The process of Claim 3 wherein the cathepsin B proteinase is secreted thiol proteinase from malignant tumors with a molecular weight of about 36,000 and stable under alkaline pH conditions. λ 10. A process of producing a monospecific antiserum to the cathepsin B like thiol proteinase secreted by malignant tumors comprising essentially the steps of: (a) producing a proteinase emulsion by homogenizing the purified tumor proteinase after dialyzing to remove ampholines; (b) injecting the proteinase emulsion intramuscularly into an animal; (c) reinjeeting the animal with the proteinase emulsion; (d) withdrawing blood of the animal after sufficient time elapses for antibody production; and (e) isolating the monospecific antiserum from the blood. 11. The- process of Claim 10 wherein the blood of the animal is withdrawn 11 days after the second injection of proteinase emulsion. 12. The process of Claim 10 wherein the enzyme is dialyzed against 50 mM sodium acetate, 200 mM NaCl and 1 mM EDTA at pH 5.5. 13. The process of Claim 10 wherein the purified cathepsin B-like proteinase is further purified by isoelectric focusing in a Sephadex G-75 superfine flat bed with a 2 percent pH 4 to 6 ampholine (BioRad) gradient. 14. The process of Claim 10 wherein the animal is reinjected with proteinase emulsion after two weeks. 15. The process of Claims 10 wherein the proteinase is homogenized with an adjuvant. ... OM

Inventors: MORT JOHN S, POOLE ALAN ROBIN, RECKLIES ANNELIESE D, MORT, JOHN, S., POOLE, ALAN, ROBIN, RECKLIES, ANNELIESE, D.
Applicants: SHRINERS HOSPITALS FOR CRIPPLE, SHRINERS HOSPITALS FOR CRIPPLED CHILDREN
Application year: 1982
Main classification: A61K39
IPC codes: C07K16